Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis

International Journal of Antimicrobial Agents

Volumn 36, Issue 6, 2010, Pages 542-544

  Lefebvre, M ^a   Jacqueline, C ^a   Amador, G ^a   Le Mabecque, V ^a   Miegeville, A ^a   Potel, G ^a   Caillon, J ^a   Asseray, N ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Daptomycin; MRSA; Osteomyelitis model; Rifampicin

Indexed keywords

DAPTOMYCIN; METICILLIN; RIFAMPICIN; VANCOMYCIN;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BONE MARROW; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; FEMALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; SYNOVIAL FLUID;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BONE AND BONES; BONE MARROW; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; JOINTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; RABBITS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 78249253326     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.008     Document Type: Article

References (20)

1. Lew D.P., Waldvogel F.A. Osteomyelitis. Lancet 2004, 364:369-379.
2. La Société de Pathologie Infectieuse de Langue Française (SPILF), et al. Clinical practice recommendations. Osteoarticular infections on materials (prosthesis, implant, osteosynthesis) [in French]. Med Mal Infect 2009;39:815-63.
3. Zimmerli W., Trampuz A., Ochsner P.E. Prosthetic-joint infections. N Engl J Med 2004, 351:1645-1654.
4. Critchley I.A., Draghi D.C., Sahm D.F., Thornsberry C., Jones M.E., Karlowsky J.A. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003, 51:639-649.
5. Sader H.S., Streit J.M., Fritsche T.R., Jones R.N. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006, 12:844-852.
6. Wootton M., MacGowan A.P., Walsh T.R. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006, 50:4195-4197.
7. John A.K., Baldoni D., Haschke M., Rentsch K., Schaerli P., Zimmerli W., et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009, 53:2719-2724.
8. Norden C.W., Niederriter K. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with LY146032. Infection 1988, 16:27.
9. Mader J.T., Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989, 33:689-692.
10. Luu Q.N., Buxton T.B., Nelson D.R., Rissing J.P. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 1989, 8:562-563.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
12. Bugnon D., Potel G., Caillon J., Baron D., Drugeon H.B., Feigel P., et al. In vivo simulation of human pharmacokinetics in the rabbit. Bull Math Biol 1998, 60:545-567.
13. Dvorchik B.H., Brazier D., DeBruin M.F., Arbeit R.D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003, 47:1318-1323.
14. Asseray N., Jacqueline C., Le Mabecque V., Batard E., Bugnon D., Potel G., et al. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Antimicrob Agents Chemother 2005, 49:857-859.
15. Saleh-Mghir A., Ameur N., Muller-Serieys C., Ismael F., Lemaitre F., Massias L., et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 2002, 46:1122-1124.
16. Amador G., Gautier H., Le Mabecque V., Miegeville A.F., Potel G., Bouler J.M., et al. In vivo assessment of the antimicrobial activity of a calcium-deficient apatite vancomycin drug delivery system in a methicillin-resistant Staphylococcus aureus rabbit osteomyelitis experimental model. Antimicrob Agents Chemother 2010, 54:950-952.
17. Rose W.E., Leonard S.N., Rybak M.J. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008, 52:3061-3067.
18. Baltch A.L., Ritz W.J., Bopp L.H., Michelsen P., Smith R.P. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother 2008, 52:1829-1833.
19. Roveta S., Marchese A., Schito G.C. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int J Antimicrob Agents 2008, 31:321-328.
20. Yin L.Y., Lazzarini L., Li F., Stevens C.M., Calhoun J.H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, 55:995-1002.